PCPP (poly[di(carboxylatophenoxy)-phosphazene]) microparticles co-encapsulating ovalbumin and CpG oligo-deoxynucleotides are potent enhancers of antigen specific Th1 immune responses in mice

Vaccine

Volumn 28, Issue 52, 2010, Pages 8306-8314

  Garlapati, Srinivas ^a   Eng, Nelson F ^a   Wilson, Heather L ^a   Buchanan, Rachelle ^a   Mutwiri, George K ^a,b   Babiuk, Lorne A ^c   Gerdts, Volker ^a,b  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

CpG; Microparticles; Polyphosphazene

Indexed keywords

ADJUVANT; CPG OLIGODEOXYNUCLEOTIDE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; OVALBUMIN; POLY[DI(CARBOXYLATOPHENOXY)PHOSPHAZENE]; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; IMMUNE RESPONSE; IMMUNIZATION; IN VITRO STUDY; IN VIVO STUDY; INGUINAL LYMPH NODE; MICROENCAPSULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TH1 CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; DRUG CARRIERS; IMMUNOGLOBULIN G; INJECTIONS, SUBCUTANEOUS; LYMPH NODES; MICE; MICE, INBRED BALB C; MICROSPHERES; OLIGODEOXYRIBONUCLEOTIDES; ORGANOPHOSPHORUS COMPOUNDS; OVALBUMIN; POLYMERS; TH1 CELLS; WHOLE BODY IMAGING;

EID: 78649739626     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.09.080     Document Type: Article

References (52)

1. De Gregorio E., Tritto E., Rappuoli R. Alum adjuvanticity: unraveling a century old mystery. Eur J Immunol 2008, 38(8 (August)):2068-2071.
2. Mosca F., Tritto E., Muzzi A., Monaci E., Bagnoli F., Iavarone C., et al. Molecular and cellular signatures of human vaccine adjuvants. Proc Natl Acad Sci USA 2008, 105(30 (July)):10501-10506.
3. Petrovsky N., Aguilar J.C. Vaccine adjuvants: current state and future trends. Immunol Cell Biol 2004, 82(5 (October)):488-496.
4. Weiner G.J., Liu H.M., Wooldridge J.E., Dahle C.E., Krieg A.M. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci USA 1997, 94(20 (September)):10833-10837.
5. Blander J.M., Medzhitov R. Regulation of phagosome maturation by signals from toll-like receptors. Science 2004, 304(5673 (May)):1014-1018.
6. Hartmann G., Weiner G.J., Krieg A.M. CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. Proc Natl Acad Sci USA 1999, 96(16 (August)):9305-9310.
7. Krieg A.M. CpG DNA: trigger of sepsis, mediator of protection, or both?. Scand J Infect Dis 2003, 35(9):653-659.
8. Warren T.L., Dahle C.E., Weiner G.J. CpG oligodeoxynucleotides enhance monoclonal antibody therapy of a murine lymphoma. Clin Lymphoma 2000, 1(1 (June)):57-61.
9. Sands H., Gorey-Feret L.J., Cocuzza A.J., Hobbs F.W., Chidester D., Trainor G.L. Biodistribution and metabolism of internally 3H-labeled oligonucleotides. I. Comparison of a phosphodiesterand a phosphorothioate. Mol Pharmacol 1994, 45(5 (May)):932-943.
10. Wedlock D.N., Skinner M.A., de Lisle G.W., Vordermeier H.M., Hewinson R.G., Hecker R., et al. Vaccination of cattle with Mycobacterium bovis culture filtrate proteins and CpG oligodeoxynucleotides induces protection against bovine tuberculosis. Vet Immunol Immunopathol 2005, 106(1-2 (June)):53-63.
11. McCluskie M.J., Davis H.L. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J Immunol 1998, 161(9 (November)):4463-4466.
12. Oxenius A., Martinic M.M., Hengartner H., Klenerman P. CpG-containing oligonucleotides are efficient adjuvants for induction of protective antiviral immune responses with T-cell peptide vaccines. J Virol 1999, 73(5 (May)):4120-4126.
13. Schneeberger A., Wagner C., Zemann A., Luhrs P., Kutil R., Goos M., et al. CpG motifs are efficient adjuvants for DNA cancer vaccines. J Invest Dermatol 2004, 123(2 (August)):371-379.
14. Singh M., Kazzaz J., Chesko J., Soenawan E., Ugozzoli M., Giuliani M., et al. Anionic microparticles are a potent delivery system for recombinant antigens from Neisseria meningitidis serotype B. J Pharm Sci 2004, 93(2 (February)):273-282.
15. Woo S.J., Kim C.H., Park M.Y., Kim H.S., Sohn H.J., Park J.S., et al. Co-administration of carcinoembryonic antigen and HIV TAT fusion protein with CpG-oligodeoxynucleotide induces potent antitumor immunity. Cancer Sci 2008, 99(5 (May)):1034-1039.
16. Heit A., Schmitz F., O'Keeffe M., Staib C., Busch D.H., Wagner H., et al. Protective CD8 T cell immunity triggered by CpG-protein conjugates competes with the efficacy of live vaccines. J Immunol 2005, 174(7 (April)):4373-4380.
17. Mullen G.E., Giersing B.K., Ajose-Popoola O., Davis H.L., Kothe C., Zhou H., et al. Enhancement of functional antibody responses to AMA1-C1/Alhydrogel, a Plasmodium falciparum malaria vaccine, with CpG oligodeoxynucleotide. Vaccine 2006, 24(14 (March)):2497-2505.
18. Qian F., Rausch K.M., Muratova O., Zhou H., Song G., Diouf A., et al. Addition of CpG ODN to recombinant Pseudomonas aeruginosa ExoProtein A conjugates of AMA1 and Pfs25 greatly increases the number of responders. Vaccine 2008, 26(20 (May)):2521-2527.
19. Zhang X.Q., Dahle C.E., Baman N.K., Rich N., Weiner G.J., Salem A.K. Potent antigen-specific immune responses stimulated by codelivery of CpG ODN and antigens in degradable microparticles. J Immunother 2007, 30(5 (July-August)):469-478.
20. Badiee A., Jaafari M.R., Samiei A., Soroush D., Khamesipour A. Coencapsulation of CpG oligodeoxynucleotides with recombinant Leishmania major stress-inducible protein 1 in liposome enhances immune response and protection against leishmaniasis in immunized BALB/c mice. Clin Vaccine Immunol 2008, 15(4 (April)):668-674.
21. Krishnamachari Y., Salem A.K. Innovative strategies for co-delivering antigens and CpG oligonucleotides. AdvDrug Deliv Rev 2009, 61(3 (March)):205-217.
22. McNeal M.M., Rae M.N., Ward R.L. Effects of different adjuvants on rotavirus antibody responses and protection in mice following intramuscular immunization with inactivated rotavirus. Vaccine 1999, 17(11-12 (March)):1573-1580.
23. Payne L.G., Andrianov A.K. Protein release from polyphosphazene matrices. Adv Drug Deliv Rev 1998, 31(3 (May)):185-196.
24. Wu J.Y., Wade W.F., Taylor R.K. Evaluation of cholera vaccines formulated with toxin-coregulated pilin peptide plus polymer adjuvant in mice. Infect Immun 2001, 69(12 (December)):7695-7702.
25. Andrianov A.K., Chen J., Payne L.G. Preparation of hydrogel microspheres by coacervation of aqueous polyphosphazene solutions. Biomaterials 1998, 19(1-3 (January-February)):109-115.
26. Andrianov A.K., Svirkin Y.Y., LeGolvan M.P. Synthesis and biologically relevant properties of polyphosphazene polyacids. Biomacromolecules 2004, 5(5 (September-October)):1999-2006.
27. Garlapati S., Facci M., Polewicz M., Strom S., Babiuk L.A., Mutwiri G., et al. Strategies to link innate and adaptive immunity when designing vaccine adjuvants. Vet Immunol Immunopathol 2009, 128(1-3 (March)):184-191.
28. Duysen E.G., Lockridge O. Whole body and tissue imaging of the butyrylcholinesterase knockout mouse injected with near infrared dye labeled butyrylcholinesterase. Chem Biol Interact 2008, 175(1-3 (September)):119-124.
29. Payne L.G., Jenkins S.A., Andrianov A., Roberts B.E. Water-soluble phosphazene polymers for parenteral and mucosal vaccine delivery. Pharm Biotechnol 1995, 6:473-493.
30. Payne L.G., Jenkins S.A., Woods A.L., Grund E.M., Geribo W.E., Loebelenz J.R., et al. Poly[di(carboxylatophenoxy)phosphazene] (PCPP) is a potent immunoadjuvant for an influenza vaccine. Vaccine 1998, 16(1 (January)):92-98.
31. Mapletoft J.W., Oumouna M., Kovacs-Nolan J., Latimer L., Mutwiri G., Babiuk L.A., et al. Intranasal immunization of mice with a formalin-inactivated bovine respiratory syncytial virus vaccine co-formulated with CpG oligodeoxynucleotides and polyphosphazenes results in enhanced protection. J Gen Virol 2008, 89(Pt 1 (January)):250-260.
32. Taghavi A., Allan B., Mutwiri G., Foldvari M., Van Kessel A., Willson P., et al. Enhancement of immunoprotective effect of CpG-ODN by formulation with polyphosphazenes against E. coli septicemia in neonatal chickens. Curr Drug Deliv 2009, 6(1 (January)):76-82.
33. Malyala P., O'Hagan D.T., Singh M. Enhancing the therapeutic efficacy of CpG oligonucleotides using biodegradable microparticles. Adv Drug Deliv Rev 2009, 61(3 (March)):218-225.
34. Malyala P., Chesko J., Ugozzoli M., Goodsell A., Zhou F., Vajdy M., et al. The potency of the adjuvant, CpG oligos, is enhanced by encapsulation in PLG microparticles. J Pharm Sci 2008, 97(3 (March)):1155-1164.
35. Jiao X., Wang R.Y., Qiu Q., Alter H.J., Shih J.W. Enhanced hepatitis C virus NS3 specific Th1 immune responses induced by co-delivery of protein antigen and CpG with cationic liposomes. J Gen Virol 2004, 85(Pt 6 (June)):1545-1553.
36. Li W.M., Dragowska W.H., Bally M.B., Schutze-Redelmeier M.P. Effective induction of CD8+T-cell response using CpG oligodeoxynucleotides and HER-2/neu-derived peptide co-encapsulated in liposomes. Vaccine 2003, 21(23 (July)):3319-3329.
37. Bourquin C., Anz D., Zwiorek K., Lanz A.L., Fuchs S., Weigel S., et al. Targeting CpG oligonucleotides to the lymph node by nanoparticles elicits efficient antitumoral immunity. J Immunol 2008, 181(5 (September)):2990-2998.
38. Bhat A.A., Seth R.K., Babu J., Biswas S., Rao D.N. Induction of mucosal and systemic humoral immune responses in murine system by intranasal immunization with peptide antigens of P. vivax and CpG oligodeoxynucleotide (ODN) in microparticle delivery. Int Immunopharmacol 2009.
39. Borges O., Cordeiro-da-Silva A., Tavares J., Santarem N., de Sousa A., Borchard G., et al. Immune response by nasal delivery of hepatitis B surface antigen and codelivery of a CpG ODN in alginate coated chitosan nanoparticles. Eur J Pharm Biopharm 2008, 69(2 (June)):405-416.
40. Pun P.B., Bhat A.A., Mohan T., Kulkarni S., Paranjape R., Rao D.N. Intranasal administration of peptide antigens of HIV with mucosal adjuvant CpG ODN coentrapped in microparticles enhances the mucosal and systemic immune responses. Int Immunopharmacol 2009, 9(4 (April)):468-477.
41. Eldridge J.H., Meulbroek J.A., Staas J.K., Tice T.R., Gilley R.M. Vaccine-containing biodegradable microspheres specifically enter the gut-associated lymphoid tissue following oral administration and induce a disseminated mucosal immune response. Adv Exp Med Biol 1989, 251:191-202.
42. Tabata Y., Ikada Y. Macrophage activation for antitumour function by muramyl dipeptide-protein conjugates. J Pharm Pharmacol 1990, 42(1 (January)):13-19.
43. Katare Y.K., Muthukumaran T., Panda A.K. Influence of particle size, antigen load, dose and additional adjuvant on the immune response from antigen loaded PLA microparticles. Int J Pharm 2005, 301(1-2 (September)):149-160.
44. Raghuvanshi R.S., Katare Y.K., Lalwani K., Ali M.M., Singh O., Panda A.K. Improved immune response from biodegradable polymer particles entrapping tetanus toxoid by use of different immunization protocol and adjuvants. Int J Pharm 2002, 245(1-2 (October)):109-121.
45. Eldridge J.H., Staas J.K., Meulbroek J.A., Tice T.R., Gilley R.M. Biodegradable and biocompatible poly(dl-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies. Infect Immun 1991, 59(9 (September)):2978-2986.
46. Andrianov A.K., Marin A., Roberts B.E. Polyphosphazene polyelectrolytes: a link between the formation of noncovalent complexes with antigenic proteins and immunostimulating activity. Biomacromolecules 2005, 6(3 (May-June)):1375-1379.
47. Heit A., Schmitz F., Haas T., Busch D.H., Wagner H. Antigen co-encapsulated with adjuvants efficiently drive protective T cell immunity. Eur J Immunol 2007, 37(8 (August)):2063-2074.
48. Andrianov A.K., Marin A., Chen J. Synthesis, properties, and biological activity of poly[di(sodium carboxylatoethylphenoxy)phosphazene]. Biomacromolecules 2006, 7(1 (January)):394-399.
49. Decollibus D.P., Marin A., Andrianov A.K. Effect of environmental factors on hydrolytic degradation of water-soluble polyphosphazene polyelectrolyte in aqueous solutions. Biomacromolecules 2010, 11(8):2033-2038.
50. Heikenwalder M., Polymenidou M., Junt T., Sigurdson C., Wagner H., Akira S., et al. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat Med 2004, 10(2 (February)):187-192.
51. Gray D., Skarvall H. B-cell memory is short-lived in the absence of antigen. Nature 1988, 336(6194 (November)):70-73.
52. Mutwiri G., Benjamin P., Soita H., Babiuk L.A. Co-administration of polyphosphazenes with CpG oligodeoxynucleotides strongly enhances immune responses in mice immunized with Hepatitis B virus surface antigen. Vaccine 2008, 26(22 (May)):2680-2688.